Novaliq’s NovaTears® treatment for evaporative dry eye disease launches in New Zealand and receives registrational approval in Australia

Heidelberg, Germany – October 30, 2017 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the launch of NovaTears® in New Zealand and registrational approval in Australia. According to McCarty, the prevalence of dry eye disease (DED) is approximately…